Join our team

Hyrax Biosciences, through its Exatype platform, delivers scalable HIV drug-resistance analysis to global programmes - processing over 150,000 HIV sequences for 1,146 active users across 70+ organisations in 103 countries. More than half of these programmes operate in Global Health Equity settings, positioning Exatype as one of the most widely adopted and trusted platforms for routine Sanger-based HIV genotyping worldwide. Building on this foundation, Hyrax Biosciences validated whether Illumina NGS generated using the Thermo Fisher HIV-1 Genotyping Kit with Integrase, when analysed on Exatype, delivers drug-resistance results equivalent to the Sanger (capillary electrophoresis sequencing) gold standard. This analysis shows strong cross-platform concordance, demonstrating that the kit performs consistently whether sequenced on Illumina or Sanger. Exatype was used as the common analytical pipeline, ensuring standardised processing and fully comparable outputs.

Exatype, developed by Hyrax Biosciences, underpins HIV drug-resistance testing for programmes worldwide, supporting more than 1,100 active users across 70+ organisations in 103 countries and processing over 150,000 HIV sequences to date. Its broad adoption - particularly across Global Health Equity settings - has established Exatype as a trusted platform for routine Sanger-based HIV-1 genotyping and reporting. Given this widespread adoption, Hyrax Biosciences evaluated whether data generated using the Thermo Fisher ABI HIV-1 Genotyping Kit with Integrase, when sequenced on Oxford Nanopore Technologies (ONT), delivers drug-resistance results equivalent to those generated from Sanger sequencing, with both datasets analysed using the Exatype platform. These findings show that the assay performs consistently across both technologies, with strong concordance in consensus sequences and drug-resistance calls. Exatype served as the shared analytical workflow, enabling direct comparison and simplifying cross-platform interpretation.